Research programme: anti-interleukin 1-beta antibodies - UCB
Alternative Names: Anti-interleukin-1-beta antibodies research programme - CelltechLatest Information Update: 06 Mar 2006
At a glance
- Originator UCB
- Class
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 06 Mar 2006 No development reported - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
- 19 Sep 2002 Celltech Group has entered a manufacturing and supply agreement with Biochemie
- 24 Jul 2001 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)